Infection due to parvovirus B19 in patients infected with human immunodeficiency virus.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Infection due to parvovirus B19 in patients infected with human immunodeficiency virus.

Clin Infect Dis. 1995 Jan;20(1):170-3. Unique Identifier : AIDSLINE MED/95244728
Chernak E; Dubin G; Henry D; Naides SJ; Hodinka RL; MacGregor RR; Friedman HM; Department of Medicine, Hospital of the University of; Pennsylvania.

Abstract: Parvovirus B19 has been described as a cause of chronic anemia in immunosuppressed patients, including those infected with human immunodeficiency virus (HIV). In this study serological assays and the polymerase chain reaction (PCR) were used to establish the prevalence of both prior and active infection due to parvovirus B19 among a general population of 105 HIV-infected individuals (cohort I) and among 22 HIV-infected patients with anemia (cohort II). Eight individuals in cohort I (7.6%) had IgG antibodies to parvovirus B19, while none had B19-specific IgM antibodies. In cohort II, four patients (18.2%) had B19-specific IgG antibodies and none had IgM antibodies. Only one person in cohort I (0.95%) and one person in cohort II (4.5%) had evidence on PCR of persistent infection with parvovirus B19; both of these patients lacked IgG and IgM antibodies to parvovirus. Both individuals with B19 viremia were anemic and had CD4 lymphocyte counts suggesting advanced immunosuppression (< 50/mm3). The observed low prevalences of B19 seropositivity and active B19 infection differ from the rates documented in previous studies and indicate that infection with parvovirus B19 is uncommon in some groups of HIV-infected patients.

Keywords: Adult Aged Anemia/COMPLICATIONS/IMMUNOLOGY/VIROLOGY Antibodies, Viral/BLOOD AIDS-Related Opportunistic Infections/*COMPLICATIONS/IMMUNOLOGY/ VIROLOGY Erythema Infectiosum/*COMPLICATIONS/IMMUNOLOGY/VIROLOGY Female Human IgG/BLOOD IgM/BLOOD Male Middle Age Parvovirus B19, Human/GENETICS/IMMUNOLOGY/ISOLATION & PURIF Polymerase Chain Reaction Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
950830
M9580960

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .